Japanese journal of clinical oncology · 2026
Evaluating the super T2-FLAIR mismatch sign in non-contrast-enhancing oligodendroglioma, IDH-mutant, and 1p/19q codeleted.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ozono Iori, Yamasaki Fumiyuki, Onishi Shumpei, Yonezawa Ushio, Taguchi Akira, Khairunnisa Novita Ikbar, Amatya Vishwa Jeet, Takeshima Yukio, Horie Nobutaka
Аннотация
BACKGROUND: The super T2-weighted imaging-fluid-attenuated inversion recovery (T2-FLAIR) mismatch sign has been identified as a prognostic imaging biomarker for non-contrast-enhancing astrocytoma, isocitrate dehydrogenase (IDH)-mutant, central nervous system World Health Organization grade 2 or 3. However, its relevance to other gliomas remains uncertain. Here, we evaluated the significance of the super T2-FLAIR mismatch sign in non-contrast-enhancing oligodendroglioma, IDH-mutant, and 1p/19q codeleted.
METHODS: We retrospectively analyzed oligodendroglioma cases from our institution and The Cancer Genome Atlas (TCGA)/The Cancer Imaging Archive lower-grade glioma (LGG) dataset. The super T2-FLAIR mismatch sign was defined as a markedly low signal, comparable to cerebrospinal fluid, in noncystic lesions, distinct from the conventional T2-FLAIR mismatch sign. We assessed its association with prognosis and diagnostic utility by including 33 non-contrast-enhancing astrocytoma cases from our institution and 30 from TCGA-LGG, calculating the positive predictive value (PPV) and negative predictive value (NPV).
RESULTS: Among 19 non-contrast-enhancing oligodendroglioma cases in our dataset and 16 in TCGA-LGG, the T2-FLAIR mismatch sign was present in 1 and 3 cases, respectively, while the super T2-FLAIR mismatch sign was observed in 3 and 2 cases. The mean follow-up period was 38.8 months (our dataset) and 28.2 months (TCGA-LGG). The super T2-FLAIR mismatch sign was not associated with either progression-free or overall survival in oligodendroglioma. In TCGA-LGG, it had a PPV of 86.7% and an NPV of 45.2% (P = 0.0487) for astrocytoma.
CONCLUSIONS: The super T2-FLAIR mismatch sign was primarily observed in astrocytoma but also appeared in non-contrast-enhancing oligodendroglioma. It served as a prognostic biomarker for astrocytoma but not for oligodendroglioma.
METHODS: We retrospectively analyzed oligodendroglioma cases from our institution and The Cancer Genome Atlas (TCGA)/The Cancer Imaging Archive lower-grade glioma (LGG) dataset. The super T2-FLAIR mismatch sign was defined as a markedly low signal, comparable to cerebrospinal fluid, in noncystic lesions, distinct from the conventional T2-FLAIR mismatch sign. We assessed its association with prognosis and diagnostic utility by including 33 non-contrast-enhancing astrocytoma cases from our institution and 30 from TCGA-LGG, calculating the positive predictive value (PPV) and negative predictive value (NPV).
RESULTS: Among 19 non-contrast-enhancing oligodendroglioma cases in our dataset and 16 in TCGA-LGG, the T2-FLAIR mismatch sign was present in 1 and 3 cases, respectively, while the super T2-FLAIR mismatch sign was observed in 3 and 2 cases. The mean follow-up period was 38.8 months (our dataset) and 28.2 months (TCGA-LGG). The super T2-FLAIR mismatch sign was not associated with either progression-free or overall survival in oligodendroglioma. In TCGA-LGG, it had a PPV of 86.7% and an NPV of 45.2% (P = 0.0487) for astrocytoma.
CONCLUSIONS: The super T2-FLAIR mismatch sign was primarily observed in astrocytoma but also appeared in non-contrast-enhancing oligodendroglioma. It served as a prognostic biomarker for astrocytoma but not for oligodendroglioma.